miR-15a-5p outperforms anti-VEGF drug in ocular neovascularization by providing dual anti-angiogenic and neuroprotective effects. [PDF]
TheranosticsZhang H +12 more
europepmc +1 more source
Biosimilars of anti-VEGF agents in retinal diseases: a narrative review of regulatory, clinical, and pharmacoeconomic aspects. [PDF]
Int J Retina VitreousZong Y, Fan Q, Huang L.
europepmc +1 more source
Real-World Persistence with Anti-VEGF Therapy in Neovascular Age-related Macular Degeneration. [PDF]
Ophthalmol TherElham A +6 more
europepmc +1 more source
Eye Drop Development of Anti-VEGF Therapeutics by Ocular Penetrating Carrier to the Posterior Region of the Eye. [PDF]
Transl Vis Sci TechnolChiueh VC +5 more
europepmc +1 more source
Time to Exudative Recurrence After Complete Fluid Resolution Following Anti-VEGF Loading in Neovascular Age-Related Macular Degeneration. [PDF]
J Clin MedKook K, Park D, Lee G, Ji YS.
europepmc +1 more source
Machine Learning to Predict Outcomes of Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration. [PDF]
Ophthalmol SciWright DM +5 more
europepmc +1 more source
Anti-VEGF safety in evolution: A comprehensive review of ocular and systemic considerations. [PDF]
Indian J OphthalmolVenkatesh R +9 more
europepmc +1 more source
Association of early anti-VEGF Therapy anatomical response with renal function and OCT biomarkers in diabetic macular edema. [PDF]
BMC OphthalmolChen H, Shang Y, Yang P, Zhou Y, Yuan Y.
europepmc +1 more source
ANTI-VEGF TREATMENT Safety of intravitreal anti-VEGFs during pregnancy is unclear
, 2012 Georgalas, Ilias +2 more
openaire +1 more source